Results 51 to 60 of about 2,896 (157)

Economic Burden of Chronic Lymphocytic Leukaemia in Australia

open access: yesEuropean Journal of Haematology, Volume 117, Issue 6, Page 1541-1551, December 2026.
ABSTRACT Background The treatment landscape for chronic lymphocytic leukaemia (CLL) has transformed over the past decade. This study aimed to estimate the healthcare costs and health burden associated with CLL in Australia. Methods A Markov model was developed to simulate the lifetime healthcare costs and health outcomes associated with CLL in ...
Lan Gao   +4 more
wiley   +1 more source

High Level of Component C1q Binding Protein (C1QBP) is Associated With Poor Prognosis and Dysfunction of Mast Cells in Lung Adenocarcinoma

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Background Component C1q binding protein (C1QBP) is known as an important regulator of mitochondrial plasticity and is involved in antitumor immune response in cancers. Nevertheless, its role in lung adenocarcinoma (LUAD) still remains largely unknown.
Wei Li   +9 more
wiley   +1 more source

Age, Comorbidity Burden and Treatment Outcomes in Mature B‐Cell Lymphoproliferative Disorders: A Real‐World Study

open access: yesCancer Medicine, Volume 15, Issue 11, November 2026.
ABSTRACT Introduction Treatment decisions in older patients with mature B‐cell lymphoproliferative disorders (MBLD) are frequently guided by chronological age and comorbidity burden, although their ability to predict clinically relevant outcomes remains uncertain.
Kevin Nasrinfar   +6 more
wiley   +1 more source

Indirect Comparisons of the Efficacy and Safety of Zanubrutinib versus Venetoclax plus Obinutuzumab in Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

open access: yesOncology and Therapy
Introduction Compared with chemoimmunotherapy, both zanubrutinib monotherapy and venetoclax plus obinutuzumab prolong progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL). Matching-adjusted indirect comparison (MAIC) can be
Talha Munir   +12 more
doaj   +1 more source

Ibrutinib, but not zanubrutinib, induces platelet receptor shedding of GPIb-IX-V complex and integrin αIIbβ3 in mice and humans

open access: yesBlood Advances, 2019
: The Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has proven to be efficacious in the treatment of B-cell chronic lymphocytic leukemia (B-CLL) and related diseases.
Gasim Dobie   +9 more
doaj   +1 more source

Impact of venetoclax‐based therapies on CLL‐associated autoimmune cytopenias: A retrospective study conducted by ERIC

open access: yesHemaSphere, Volume 10, Issue 11, November 2026.
Abstract The impact of venetoclax‐based therapies on autoimmune cytopenias (AIC) in patients with chronic lymphocytic leukemia (CLL) is largely unknown. This study aimed to evaluate preexisting and treatment‐emergent AIC in patients with CLL treated with venetoclax, focusing on the differential impact of venetoclax monotherapy versus venetoclax‐based ...
Candida Vitale   +106 more
wiley   +1 more source

Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results

open access: yesBlood Advances
: Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib (ibr) revolutionized chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treatment, although treatment-related toxicities limit the use of some BTK inhibitors.
Mazyar Shadman   +13 more
doaj   +1 more source

Fixed‐duration glofitamab in patients with relapsed or refractory follicular lymphoma: Results from a Phase 1/2 study

open access: yesHemaSphere, Volume 10, Issue 11, November 2026.
Abstract More effective options are needed to personalize treatment for relapsed/refractory (R/R) follicular lymphoma (FL) by balancing efficacy, safety, and accessibility. We report efficacy and safety of glofitamab, a CD20xCD3 T‐cell engaging bispecific antibody, from a Phase 1/2 study in patients with R/R FL after ≥2 prior therapies.
Franck Morschhauser   +19 more
wiley   +1 more source

Clinician Perspective on Once-Daily Zanubrutinib Dosing for B-Cell Malignancies at a Single Center

open access: yesClinical Medicine Insights: Oncology
Zanubrutinib, a next-generation, irreversible, highly potent, and selective Bruton tyrosine kinase inhibitor, is approved by the U.S. Food and Drug Administration to treat patients with B-cell malignancies in 2 dose regimens: 160 mg twice daily (BID) and
Mohit Narang, Courtney Horn, Edward Lee
doaj   +1 more source

A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings

open access: yesFrontiers in Immunology
BackgroundCytokine release triggered by a hyperactive immune response is thought to contribute to severe acute respiratory syndrome coronavirus 2019 (SARS-CoV-2)–related respiratory failure.
Steven P. Treon   +35 more
doaj   +1 more source

Home - About - Disclaimer - Privacy